ArticleNPJ breast cancer2021

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.

Stacey E P Joosten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.